US Broker Ratings

LifeMD, Inc. (LFMD) Stock Analysis: Exploring a 106.66% Potential Upside with Solid Buy Ratings

LifeMD, Inc. (NASDAQ: LFMD), a burgeoning player in the healthcare sector, particularly in health information services, has captured the attention of investors with its innovative direct-to-patient telehealth model. Based in..

Sonida Senior Living, Inc. (SNDA) Stock Analysis: Navigating Challenges with Strong Revenue Growth

Sonida Senior Living, Inc. (SNDA), a prominent player in the healthcare sector specializing in medical care facilities, is navigating a challenging financial landscape. With a market capitalization of $492.04 million..

Humacyte, Inc. (HUMA) Stock Analysis: Exploring a 390% Potential Upside in Biotechnology

Humacyte, Inc. (NASDAQ: HUMA), a pioneering biotechnology company based in Durham, North Carolina, is making waves in the healthcare sector with its cutting-edge approach to engineering bioengineered human tissues. The..

MeiraGTx Holdings plc (MGTX) Stock Analysis: A Biotech Gem with a Potential 215% Upside

As the biotechnology sector continues to captivate investors with its promise of groundbreaking treatments, MeiraGTx Holdings plc (NASDAQ: MGTX) stands out for its ambitious pipeline and impressive potential upside. With..

Celcuity Inc. (CELC) Stock Analysis: Biotechnology Innovator with 16.91% Potential Upside

Celcuity Inc. (NASDAQ: CELC), a prominent player in the biotechnology sector, is capturing the attention of investors with its innovative approach to cancer treatment and a promising potential upside of..

Opthea Limited (OPT) Stock Analysis: Navigating a Biotech’s Bold Phase 3 Path Amidst Market Skepticism

Opthea Limited (NASDAQ: OPT), an Australian biopharmaceutical company, commands attention within the healthcare sector for its pioneering work in the biotechnology industry. With a market capitalization of $583.1 million, Opthea..

PureTech Health plc (PRTC) Stock Analysis: Unpacking a 176% Potential Upside in the Biotech Sector

PureTech Health plc (NASDAQ: PRTC), a pioneering entity in the biotechnology space, is drawing significant attention thanks to its impressive potential upside of 176.14% as suggested by analyst target prices...

Autolus Therapeutics (AUTL) Stock Analysis: A Biotech with 541% Potential Upside

Autolus Therapeutics plc (NASDAQ: AUTL), a promising player in the biotechnology sector, is captivating investor attention with its substantial growth potential. Despite a modest market cap of $399.21 million and..

Evolus, Inc. (EOLS) Stock Analysis: Is a 179% Potential Upside Worth the Risk?

Evolus, Inc. (NASDAQ: EOLS), a dynamic player in the healthcare sector, is capturing investor attention with an enticing potential upside of 179.01%. Specializing in the cash-pay aesthetic market, Evolus offers..

Prothena Corporation plc (PRTA) Stock Analysis: A 33% Potential Upside in the Biotech Sector

Prothena Corporation plc (NASDAQ: PRTA) is an intriguing player in the biotechnology sector, focused on tackling the challenging landscape of neurodegenerative diseases and protein dysregulation disorders. Based in Ireland, Prothena..

Abivax SA (ABVX) Investor Outlook: A Biotech Stock with a 29.60% Potential Upside

Abivax SA (ABVX), a French biotechnology company, has emerged as a notable contender in the healthcare sector, attracting investor attention with its promising drug pipeline and considerable growth potential. Headquartered..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: Biotech Trailblazer with a 26.53% Upside Potential

Maze Therapeutics, Inc. (NASDAQ: MAZE) emerges as a compelling player in the biotechnology sector, boasting a market capitalization of $1.44 billion. Operating out of South San Francisco, California, Maze is..

ATAI Life Sciences (ATAI): Biotechnology Innovator with 118% Potential Upside

ATAI Life Sciences N.V. (NASDAQ: ATAI) stands at the forefront of biotechnology innovation, leveraging cutting-edge research to address pressing mental health challenges. With a compelling market capitalization of $1.48 billion,..

Cogent Biosciences, Inc. (COGT) Stock Analysis: Uncovering a 47% Potential Upside in the Biotech Sector

Cogent Biosciences, Inc. (NASDAQ: COGT) is drawing attention in the biotechnology sector with its promising potential upside of 47.12%. As a company dedicated to developing precision therapies for genetically defined..

Oric Pharmaceuticals, Inc. (ORIC) Investor Outlook: A Promising 47% Upside Potential Amid Innovative Cancer Therapies

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), a burgeoning player in the biotechnology sector, is capturing significant investor attention due to its innovative approach to combating cancer resistance mechanisms. With a market..

Fortrea Holdings Inc. (FTRE) Stock Analysis: Navigating Volatility and Strategic Collaborations in the Biotech Sector

Fortrea Holdings Inc. (FTRE), a prominent player in the biotechnology industry, has been capturing the attention of investors with its strategic initiatives and volatile stock performance. Headquartered in Durham, North..

Personalis, Inc. (PSNL) Stock Analysis: Navigating a Complex Landscape with a Strong Buy Consensus

Personalis, Inc. (NASDAQ: PSNL), a prominent player in the healthcare sector, specializes in advanced cancer genomic tests and services. Despite facing significant challenges, including negative revenue growth and a heavy..

Surmodics, Inc. (SRDX) Investor Outlook: Navigating Challenges and Opportunities in the Medical Device Sector

Surmodics, Inc. (NASDAQ: SRDX), a key player in the healthcare sector specializing in medical devices, finds itself at a critical juncture. With a market capitalization of $393.18 million, Surmodics offers..

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Unpacking a 97% Potential Upside

Rapport Therapeutics, Inc. (NASDAQ: RAPP) is capturing investor attention with its promising advancements in the biotechnology sector, specifically targeting central nervous system (CNS) disorders. With a compelling market cap of..

Kamada Ltd. (KMDA) Stock Analysis: Exploring a 104% Potential Upside in the Healthcare Sector

Kamada Ltd. (NASDAQ: KMDA), an Israel-based healthcare company specializing in plasma-derived protein therapeutics, stands in a unique position within the drug manufacturing industry. With a market capitalization of $393.91 million,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds